Multiantibody strategies for HIV

Clinical and Developmental Immunology

Volumn 2013, Issue , 2013, Pages

  Hiatt, Andrew ^a   Zeitlin, Larry ^a   Whaley, Kevin J ^a  

^a Mapp Biopharmaceutical Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; MICROBICIDE; MONOCLONAL ANTIBODY; ANTIVIRUS AGENT; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; NEUTRALIZING ANTIBODY; VIRUS ANTIGEN;

ANTIGEN SPECIFICITY; B LYMPHOCYTE; DISEASE TRANSMISSION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMORAL IMMUNITY; IMMUNE RESPONSE; NONHUMAN; PRIORITY JOURNAL; REVIEW; VACCINATION; BIOSYNTHESIS; DRUG APPROVAL; DRUG EFFECT; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNE EVASION; IMMUNOLOGY; METABOLISM; VIROLOGY; VIRUS REPLICATION; DRUG EFFECTS; HIV INFECTIONS;

ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; ANTIGENS, VIRAL; ANTIVIRAL AGENTS; DRUG APPROVAL; HIV ANTIBODIES; HIV INFECTIONS; HIV-1; HUMANS; IMMUNE EVASION; VIRUS REPLICATION;

EID: 84879290712     PISSN: 17402522     EISSN: 17402530     Source Type: Journal    
DOI: 10.1155/2013/632893     Document Type: Review

References (141)

1. Walker B. D., Burton D. R., Toward an AIDS vaccine. Science 2008 320 5877 760 764 2-s2.0-44049108744 10.1126/science.1152622
2. Heckler M.,. U.S. Health Secretary, news conference April 23, 1984
3. Nicasio M., Sautto G., Clementi N., Diotti R. A., Criscuolo E., Castelli M., Solforosi L., Clementi M., Burioni R., Neutralization interfering antibodies: a "novel" example of humoral immune dysfunction facilitating viral escape? Viruses 2012 4 9 1731 1752
4. Barouch D. H., Challenges in the development of an HIV-1 vaccine. Nature 2008 455 613 619
5. Karlsson Hedestam G. B., Fouchier R. A. M., Phogat S., Burton D. R., Sodroski J., Wyatt R. T., The challenges of eliciting neutralizing antibodies to HIV-1 and to influenza virus. Nature Reviews Microbiology 2008 6 2 143 155 2-s2.0-38349081511 10.1038/nrmicro1819
6. Ploegh H. L., Viral strategies of immune evasion. Science 1998 280 5361 248 253 2-s2.0-0032503029 10.1126/science.280.5361.248
7. Seet B. T., Johnston J. B., Brunetti C. R., Barrett J. W., Everett H., Cameron C., Sypula J., Nazarian S. H., Lucas A., McFadden G., Poxviruses and immune evasion. Annual Review of Immunology 2003 21 377 423 2-s2.0-0013098971 10.1146/annurev.immunol.21.120601.141049
8. Vossen M. T. M., Westerhout E. M., Söderberg-Nauclér C., Wiertz E. J. H. J., Viral immune evasion: a masterpiece of evolution. Immunogenetics 2002 54 8 527 542 2-s2.0-0036449295 10.1007/s00251-002-0493-1
9. Taylor D. R., Hepatitis C virus: evasion of the interferon-induced antiviral response. Journal of Molecular Medicine 2000 78 4 182 190 2-s2.0-0033934327
10. Brenchley J. M., Price D. A., Schacker T. W., Asher T. E., Silvestri G., Rao S., Kazzaz Z., Bornstein E., Lambotte O., Altmann D., Blazar B. R., Rodriguez B., Teixeira-Johnson L., Landay A., Martin J. N., Hecht F. M., Picker L. J., Lederman M. M., Deeks S. G., Douek D. C., Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nature Medicine 2006 12 12 1365 1371 2-s2.0-33845532053 10.1038/nm1511
11. Le Gall S., Erdtmann L., Benichou S., Berlioz-Torrent C., Liu L., Benarous R., Heard J. M., Schwartz O., Nef interacts with the subunit of clathrin adaptor complexes and reveals a cryptic sorting signal in MHC I molecules. Immunity 1998 8 4 483 495 2-s2.0-0032055774 10.1016/S1074-7613(00) 80553-1
12. Yang O. O., Nguyen P. T., Kalams S. A., Dorfman T., Göttlinger H. G., Stewart S., Chen I. S. Y., Threlkeld S., Walker B. D., Nef-mediated resistance of human immunodeficiency virus type 1 to antiviral cytotoxic T lymphocytes. Journal of Virology 2002 76 4 1626 1631 2-s2.0-0036146227 10.1128/JVI.76.4.1626-1631.2002
13. Wyatt R., Sodroski J., The HIV-1 envelope glycoproteins: fusogens, antigens, and immunogens. Science 1998 280 5371 1884 1888 2-s2.0-0032546844 10.1126/science.280.5371.1884
14. Chun T. W., Carruth L., Finzi D., Shen X., DiGiuseppe J. A., Taylor H., Hermankova M., Chadwick K., Margolick J., Quinn T. C., Kuo Y. H., Brookmeyer R., Zeiger M. A., Barditch-Crovo P., Siliciano R. F., Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature 1997 387 6629 183 188 2-s2.0-0030913366 10.1038/387183a0
15. Korber B., Gaschen B., Yusim K., Thakallapally R., Kesmir C., Detours V., Evolutionary and immunological implications of contemporary HIV-1 variation. British Medical Bulletin 2001 58 19 42 2-s2.0-0035162494 10.1093/bmb/58.1.19
16. Ubol S., Halstead S. B., How innate immune mechanisms contribute to antibody-enhanced viral infections. Clinical and Vaccine Immunology 2010 17 12 1829 1835 2-s2.0-78649820026 10.1128/CVI.00316-10
17. Broering T. J., Garrity K. A., Boatright N. K., Sloan S. E., Sandor F., Thomas W. D., Szabo G., Finberg R. W., Ambrosino D. M., Babcock G. J., Identification and characterization of broadly neutralizing human monoclonal antibodies directed against the E2 envelope glycoprotein of hepatitis C virus. Journal of Virology 2009 83 23 12473 12482 2-s2.0-70450162452 10.1128/JVI.01138-09
18. Krey T., D'Alayer J., Kikuti C. M., Saulnier A., Damier-Piolle L., Petitpas I., Johansson D. X., Tawar R. G., Baron B., Robert B., England P., Persson M. A. A., Martin A., Rey F. A., The disulfide bonds in glycoprotein E2 of hepatitis C virus reveal the tertiary organization of the molecule. PLoS Pathogens 2010 6 2 2-s2.0-77649269513 10.1371/journal.ppat.1000762 e1000762
19. Perotti M., Mancini N., Diotti R. A., Tarr A. W., Ball J. K., Owsianka A., Adair R., Patel A. H., Clementi M., Burioni R., Identification of a broadly cross-reacting and neutralizing human monoclonal antibody directed against the hepatitis C virus E2 protein. Journal of Virology 2008 82 2 1047 1052 2-s2.0-37849016609 10.1128/JVI.01986-07
20. Burioni R., Canducci F., Mancini N., Clementi N., Sassi M., De Marco D., Saita D., Diotti R. A., Sautto G., Sampaolo M., Clementi M., Molecular cloning of the first human monoclona antibodies neutralizing with high potency Swine-origin Influenza A pandemic virus (S-OIV). New Microbiologica 2009 32 4 319 324 2-s2.0-74249110309
21. Wang Y., Keck Z. Y., Saha A., Affinity maturation to improve human monoclonal antibody neutralization potency and breadth against hepatitis C virus. Journal of Biological Chemistry 2011 286 44218 44233
22. Sabo M. C., Luca V. C., Prentoe J., Neutralizing monoclonal antibodies against hepatitis C virus E2 protein bind discontinuous epitopes and inhibit infection at a postattachment step. Journal of Virology 2011 85 7005 7019
23. Burioni R., Mancini N., Canducci F., Carletti S., Grieco A., Perotti M., Serafini G., Berardinelli E., Bighi S., Varaldo P. E., Clementi M., Humoral immune response against hepatitis C virus. Journal of Biological Regulators and Homeostatic Agents 2003 17 2 125 127 2-s2.0-12444311292
24. Bugli F., Mancini N., Kang C. Y., Di Campli C., Grieco A., Manzin A., Gabrielli A., Gasbarrini A., Fadda G., Varaldo P. E., Clementi M., Burioni R., Mapping B-cell epitopes of hepatitis C virus E2 glycoprotein using human monoclonal antibodies from phage display libraries. Journal of Virology 2001 75 20 9986 9990 2-s2.0-0034807355 10.1128/JVI.75.20.9986-9990.2001
25. Giang E., Dorner M., Prentoe J. C., Human broadly neutralizing antibodies to the envelope glycoprotein complex of hepatitis C virus. Proceedings of the National Academy of Sciences of the United States of America 2012 109 6205 6210
26. Keck Z. Y., Xia J., Wang Y., Human monoclonal antibodies to a novel cluster of conformational epitopes on HCV E2 with resistance to neutralization escape in a genotype 2a isolate. PLOS Pathogens 2012 8 e1002653
27. Burioni R., Bugli F., Mancini N., Rosa D., Di Campli C., Moroncini G., Manzin A., Abrignani S., Varaldo P. E., Clementi M., Fadda G., Nonneutralizing human antibody fragments against hepatitis C virus E2 glycoprotein modulate neutralization of binding activity of human recombinant Fabs. Virology 2001 288 1 29 35 2-s2.0-17944375718 10.1006/viro.2001.1014
28. Zhang P., Zhong L., Struble E. B., Watanabe H., Kachko A., Mihalik K., Virata-Theimer M. L., Alter H. J., Feinstone S., Major M., Depletion of interfering antibodies in chronic hepatitis C patients and vaccinated chimpanzees reveals broad cross-genotype neutralizing activity. Proceedings of the National Academy of Sciences of the United States of America 2009 106 18 7537 7541 2-s2.0-66149135701 10.1073/pnas.0902749106
29. Burioni R., Matsuura Y., Mancini N., Tani H., Miyamura T., Varaldo P. E., Clementi M., Diverging effects of human recombinant anti-hepatitis C virus (HCV) antibody fragments derived from a single patient on the infectivity of a vesicular stomatitis virus/HCV pseudotype. Journal of Virology 2002 76 22 11775 11779 2-s2.0-0036827644 10.1128/JVI.76.22.11775-11779.2002
30. Mancini N., Canducci F., Carletti S., Berardinelli E., Serafini G., Grieco A., Perotti M., Malcangi G., Danieli M. G., Varaldo P. E., Clementi M., Burioni R., Heterogeneity of the humoral anti-HCV/E2 response in persistently infected patients as demonstrated by divergent patterns of inhibition of the binding of anti-HCV/E2 human monoclonal antibodies. Journal of Biological Regulators and Homeostatic Agents 2003 17 2 183 187 2-s2.0-12444270693
31. Burioni R., Mancini N., Carletti S., Perotti M., Grieco A., Canducci F., Varaldo P. E., Clementi M., Cross-reactive pseudovirus-neutralizing anti-envelope antibodies coexist with antibodies devoid of such activity in persistent hepatitis C virus infection. Virology 2004 327 2 242 248 2-s2.0-4544331326 10.1016/j.virol.2004.06.042
32. Mancini N., Carletti S., Perotti M., Romanò L., Di Stefano Craxì R., Craxì A., Zanetti A. R., Clementi M., Burioni R., Modulation of epitope-specific anti-hepatitis C virus E2 (anti-HCV/E2) antibodies by anti-viral treatment. Journal of Medical Virology 2006 78 10 1304 1311 2-s2.0-33748652905 10.1002/jmv.20704
33. Di Lorenzo C., Angus A. G., Patel A. H., Hepatitis C virus evasion mechanisms from neutralizing antibodies. Viruses 2011 3 2280 2300
34. El Abd Y. S., Tabll A. A., El Din N. G., Neutralizing activities of caprine antibodies towards conserved regions of the HCV envelope glycoprotein E2. Virology Journal 2011 8, article 391
35. Sautto G., Mancini N., Diotti R. A., Solforosi L., Clementi M., Burioni R., Anti-hepatitis C virus E2 (HCV/E2) glycoprotein monoclonal antibodies and neutralization interference. Antiviral Research 2012 96 82 89
36. Rothman A. L., Immunity to dengue virus: a tale of original antigenic sin and tropical cytokine storms. Nature Reviews Immunology 2011 11 8 532 543 2-s2.0-79960835805 10.1038/nri3014
37. Muller S., Avoiding deceptive imprinting of the immune response to HIV-1 infection in vaccine development. International Reviews of Immunology 2004 23 5-6 423 436 2-s2.0-4644285658 10.1080/08830180490432802
38. Murphy B. R., Whitehead S. S., Immune response to dengue virus and prospects for a vaccine. Annual Review of Immunology 2011 29 587 619
39. Sabchareon A., Wallace D., Sirivichayakul C., Protective efficacy of the recombinant, live-attenuated CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial. Lancet 2012 380 9853 1559 1567
40. Clementi N., De Marco D., Mancini N., A human monoclonal antibody with neutralizing activity against highly divergent influenza subtypes. PLoS ONE 2011 6 e28001
41. Sui J., Hwang W. C., Perez S., Wei G., Aird D., Chen L. M., Santelli E., Stec B., Cadwell G., Ali M., Wan H., Murakami A., Yammanuru A., Han T., Cox N. J., Bankston L. A., Donis R. O., Liddington R. C., Marasco W. A., Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses. Nature Structural and Molecular Biology 2009 16 3 265 273 2-s2.0-62049083943 10.1038/nsmb.1566
42. Knossow M., Gaudier M., Douglas A., Barrère B., Bizebard T., Barbey C., Gigant B., Skehel J. J., Mechanism of neutralization of influenza virus infectivity by antibodies. Virology 2002 302 2 294 298 2-s2.0-0036441307 10.1006/viro.2002.1625
43. De Marco D., Clementi N., Mancini N., A non-VH1-69 heterosubtypic neutralizing human monoclonal antibody protects mice against H1N1 and H5N1 viruses. PLoS ONE 2012 7 e34415
44. Burioni R., Canducci F., Mancini N., Clementi N., Sassi M., De Marco D., Diotti R. A., Saita D., Sampaolo M., Sautto G., Pianezze M., Clementi M., Monoclonal antibodies isolated from human B cells neutralize a broad range of H1 subtype influenza A viruses including swine-origin Influenza virus (S-OIV). Virology 2010 399 1 144 152 2-s2.0-77049088439 10.1016/j.virol.2009.12.014
45. To K. K., Zhang A. J., Hung I. F., High titer and avidity of nonneutralizing antibodies against influenza vaccine antigen are associated with severe influenza. Clinical and Vaccine Immunology 2012 19 1012 1018
46. Elhefnawi M., Alaidi O., Mohamed N., Kamar M., El-Azab I., Zada S., Siam R., Identification of novel conserved functional motifs across most Influenza A viral strains. Virology Journal 2011 8, article 44 2-s2.0-79251550432 10.1186/1743-422X-8-44
47. Solforosi L., Mancini N., Canducci F., A phage display vector optimized for the generation of human antibody combinatorial libraries and the molecular cloning of monoclonal antibody fragments. New Microbiologica 2012 35 289 294
48. Ndifon W., Wingreen N. S., Levin S. A., Differential neutralization efficiency of hemagglutinin epitopes, antibody interference, and the design of influenza vaccines. Proceedings of the National Academy of Sciences of the United States of America 2009 106 21 8701 8706 2-s2.0-66649100756 10.1073/pnas.0903427106
49. Zhou Z., Post P., Chubet R., Holtz K., McPherson C., Petric M., Cox M., A recombinant baculovirus-expressed S glycoprotein vaccine elicits high titers of SARS-associated coronavirus (SARS-CoV) neutralizing antibodies in mice. Vaccine 2006 24 17 3624 3631 2-s2.0-33645235641 10.1016/j.vaccine.2006.01.059
50. Perlman S., Dandekar A. A., Immunopathogenesis of coronavirus infections: implications for SARS. Nature Reviews Immunology 2005 5 12 917 927 2-s2.0-28544437130 10.1038/nri1732
51. Zhong L., Haynes L., Struble E. B., Tamin A., Virata-Theimer M. L., Zhang P., Antibody-mediated synergy and interference in the neutralization of SARS-CoV at an epitope cluster on the spike protein. Biochemical and Biophysical Research Communications 2009 390 3 1056 1060 2-s2.0-70449697853 10.1016/j.bbrc.2009.10.115
52. Tripp R. A., Haynes L. M., Moore D., Anderson B., Tamin A., Harcourt B. H., Jones L. P., Yilla M., Babcock G. J., Greenough T., Ambrosino D. M., Alvarez R., Callaway J., Cavitt S., Kamrud K., Alterson H., Smith J., Harcourt J. L., Miao C., Razdan R., Comer J. A., Rollin P. E., Ksiazek T. G., Sanchez A., Rota P. A., Bellini W. J., Anderson L. J., Monoclonal antibodies to SARS-associated coronavirus (SARS-CoV): identification of neutralizing and antibodies reactive to S, N, M and e viral proteins. Journal of Virological Methods 2005 128 1-2 21 28 2-s2.0-22144475392 10.1016/j.jviromet.2005.03.021
53. Coughlin M. M., Prabhakar B. S., Neutralizing human monoclonal antibodies to severe acute respiratory syndrome coronavirus: target, mechanism of action, and therapeutic potential. Reviews in Medical Virology 2012 22 2 17
54. Richman D. D., Wrin T., Little S.J., Petropoulos C.J., Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proceedings of the National Academy of Sciences of the United States of America 2003 100 4144 4149
55. Phillips R. E., Rowland-Jones S., Nixon D. F., Gotch F. M., Edwards J. P., Ogunlesi A. O., Elvin J. G., Rothbard J. A., Bangham C. R. M., Rizza C. R., McMichael A. J., Human immunodeficiency virus genetic variation that can escape cytotoxic T cell recognition. Nature 1991 354 6353 453 459 2-s2.0-0025827529 10.1038/354453a0
56. Canducci F., Marinozzi M. C., Sampaolo M., Berrè S., Bagnarelli P., Degano M., Gallotta G., Mazzi B., Lemey P., Burioni R., Clementi M., Dynamic features of the selective pressure on the human immunodeficiency virus type 1 (HIV-1) gp120 CD4-binding site in a group of long term non progressor (LTNP) subjects. Retrovirology 2009 6, article 4 2-s2.0-60849133898 10.1186/1742-4690-6-4
57. Zwick M. B., Wang M., Poignard P., Stiegler G., Katinger H., Burton D. R., Parren P. W. H. I., Neutralization synergy of human immunodeficiency virus type 1 primary isolates by cocktails of broadly neutralizing antibodies. Journal of Virology 2001 75 24 12198 12208 2-s2.0-0035202616 10.1128/JVI.75.24.12198- 12208.2001
58. Hansen J. E. S., Sorensen A. M., Olofsson S., Osinaga E., Roseto A., Combination effect on HIV infection in vitro of soluble CD4 and HIV-neutralizing antibodies. Archives of Virology 1994 134 1-2 179 184 2-s2.0-0028001866
59. Verrier F., Nádas A., Gorny M. K., Zolla-Pazner S., Additive effects characterize the interaction of antibodies involved in neutralization of the primary dualtropic human immunodeficiency virus type 1 isolate 89.6. Journal of Virology 2001 75 19 9177 9186 2-s2.0-0034856156 10.1128/JVI.75.19. 9177-9186.2001
60. Yuan W., Li X., Kasterka M., Gorny M. K., Zolla-Pazner S., Sodroski J., Oligomer-specific conformations of the Human Immunodeficiency Virus (HIV-1) gp41 envelope glycoprotein ectodomain recognized by human monoclonal antibodies. AIDS Research and Human Retroviruses 2009 25 3 319 328 2-s2.0-65449174955 10.1089/aid.2008.0213
61. Dennison S. M., Anasti K., Scearce R. M., Sutherland L., Parks R., Xia S. M., Liao H. X., Gorny M. K., Zolla-Pazner S., Haynes B. F., Alam S. M., Nonneutralizing HIV-1 gp41 envelope cluster II human monoclonal antibodies show polyreactivity for binding to phospholipids and protein autoantigens. Journal of Virology 2011 85 3 1340 1347 2-s2.0-78651388412 10.1128/JVI.01680-10
62. Gorny M. K., Zolla-Pazner S., Recognition by human monoclonal antibodies of free and complexed peptides representing the prefusogenic and fusogenic forms of human immunodeficiency virus type 1 gp41. Journal of Virology 2000 74 13 6186 6192 2-s2.0-0034046091 10.1128/JVI.74.13.6186-6192.2000
63. Clementi N., Mancini N., Solforosi L., Castelli M., Clementi M., Burioni R., Phage display-based strategies for cloning and optimization of monoclonal antibodies directed against human pathogens. International Journal of Molecular Sciences 2012 13 8273 8292
64. Mancini N., Clementi M., Burioni R., Natalizumab-associated progressive multifocal leukoencephalopathy. New England Journal of Medicine 2012 367 871 872
65. Kedzierska K., Valkenburg S. A., Doherty P. C., Davenport M. P., Venturi V., Use it or lose it: establishment and persistence of T cell memory. Frontiers in Immunology 2012 3, article 357
66. Shapiro-Shelef M., Calame K., Regulation of plasma-cell development. Nature Reviews Immunology 2005 5 230 242
67. McHeyzer-Williams L. J., McHeyzer-Williams M. G., Antigen-specific memory B cell development. Annual Review of Immunology 2005 23 487 513 2-s2.0-17644379940 10.1146/annurev.immunol.23.021704.115732
68. Jacob J., Kelsoe G., Rajewsky K., Weiss U., Intraclonal generation of antibody mutants in germinal centres. Nature 1991 354 6352 389 392 2-s2.0-0026060620 10.1038/354389a0
69. Webster R. G., Original antigenic sin in ferrets: the response to sequential infections with influenza viruses. Journal of Immunology 1966 97 2 177 183 2-s2.0-0013935657
70. Davenport F. M., Hennessy A. V., Francis T. Jr., Epidemiologic and immunologic significance of age distribution of antibody to antigenic variants of influenza virus. The Journal of Experimental Medicine 1953 98 6 641 656 2-s2.0-0001147595
71. Jensen K. E., Davenport F. M., Hennessy A. V., Francis T. Jr., Characterization of influenza antibodies by serum absorption. The Journal of Experimental Medicine 1956 104 2 199 209 2-s2.0-77049279367
72. Francis T. Jr., Influenza: the new acquaintance. Annals of Internal Medicine 1953 39 2 203 221
73. Francis T. Jr., Davenport F. M., Hennessy A. V., A serological recapitulation of human infection with different strains of influenza virus. Transactions of the Association of American Physicians 1953 66 231 239 2-s2.0-0000349947
74. Grant M. D., Antibody convergence along a common idiotypic axis in immunodeficiency virus and hepatitis C virus infections. Journal of Medical Virology 2002 66 1 13 21 2-s2.0-0036186079 10.1002/jmv.2105
75. Laoprasopwattana K., Libraty D. H., Endy T. P., Nisalak A., Chunsuttiwat S., Vaughn D. W., Reed G., Ennis F. A., Rothman A. L., Green S., Dengue virus (DV) enhancing antibody activity in preillness plasma does not predict subsequent disease severity or viremia in secondary DV infection. Journal of Infectious Diseases 2005 192 3 510 519 2-s2.0-22544457161 10.1086/431520
76. Endy T. P., Nisalak A., Chunsuttitwat S., Vaughn D. W., Green S., Ennis F. A., Rothman A. L., Libraty D. H., Relationship of preexisting dengue virus (DV) neutralizing antibody levels to viremia and severity of disease in a prospective cohort study of DV infection in Thailand. Journal of Infectious Diseases 2004 189 6 990 1000 2-s2.0-1642415963 10.1086/382280
77. Beltramello M., Williams K. L., Simmons C. P., MacAgno A., Simonelli L., Quyen N. T. H., Sukupolvi-Petty S., Navarro-Sanchez E., Young P. R., De Silva A. M., Rey F. A., Varani L., Whitehead S. S., Diamond M. S., Harris E., Lanzavecchia A., Sallusto F., The human immune response to dengue virus is dominated by highly cross-reactive antibodies endowed with neutralizing and enhancing activity. Cell Host and Microbe 2010 8 3 271 283 2-s2.0-77956605864 10.1016/j.chom.2010.08.007
78. Liao H. X., Lynch R., Zhou T., Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus. Nature 2013 496 469 476
79. Parsons M. S., Rouleau D., Routy J. P., Leblanc R., Grant M. D., Bernard N. F., Selection of human anti-HIV broadly neutralizing antibodies occurs within the context of frozen 1F7-idiotypic repertoire. AIDS 2011 25 10 1259 1264 2-s2.0-79958863431 10.1097/QAD.0b013e328347f9fa
80. Kohler H., Muller S., Nara P. L., Deceptive imprinting in the immune response against HIV-1. Immunology Today 1994 15 10 475 478 2-s2.0-0028097587 10.1016/0167-5699(94)90192-9
81. Nara P. L., Garrity R., Deceptive imprinting: a cosmopolitan strategy for complicating vaccination. Vaccine 1998 16 19 1780 1787 2-s2.0-0032211011 10.1016/S0264-410X(98)00168-6
82. Salk J., Bretscher P. A., Salk P. L., Clerici M., Shearer G. M., A strategy for prophylactic vaccination against HIV. Science 1993 260 5112 1270 1272 2-s2.0-0027205321
83. Wang H., Muller S., Zolla-Pazner S., Kohler H., Human monoclonal and polyclonal anti-human immunodeficiency virus-1 antibodies share a common clonotypic specificity. European Journal of Immunology 1992 22 7 1749 1755 2-s2.0-0026776364 10.1002/eji.1830220713
84. Clementi N., Criscuolo E., Castelli M., Clementi M., Broad-range neutralizing anti-influenza A human monoclonal antibodies: new perspectives in therapy and prophylaxis. New Microbiologica 2012 35 4 399 406
85. Kashyap A. K., Steel J., Oner A. F., Dillon M. A., Swale R. E., Wall K. M., Perry K. J., Faynboym A., Ilhan M., Horowitz M., Horowitz L., Palese P., Bhatt R. R., Lerner R. A., Combinatorial antibody libraries from survivors of the Turkish H5N1 avian influenza outbreak reveal virus neutralization strategies. Proceedings of the National Academy of Sciences of the United States of America 2008 105 16 5986 5991 2-s2.0-43149109969 10.1073/pnas.0801367105
86. Throsby M., van den Brink E., Jongeneelen M., Poon L. L. M., Alard P., Cornelissen L., Bakker A., Cox F., van Deventer E., Guan Y., Cinatl J., ter Meulen J., Lasters I., Carsetti R., Peiris M., de Kruif J., Goudsmit J., Heterosubtypic neutralizing monoclonal antibodies cross-protective against H5N1 and H1N1 recovered from human IgM+ memory B cells. PLoS ONE 2008 3 12 2-s2.0-58049198443 10.1371/journal.pone.0003942 e3942
87. Corti D., Voss J., Gamblin S. J., A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins. Science 2011 333 6044 850 856
88. Stiegler G., Kunert R., Purtscher M., Wolbank S., Voglauer R., Steindl F., Katinger H., A potent cross-clade neutralizing human monoclonal antibody against a novel epitope on gp41 of human immunodeficiency virus type 1. AIDS Research and Human Retroviruses 2001 17 18 1757 1765 2-s2.0-0035701421 10.1089/08892220152741450
89. Walker L. M., Phogat S. K., Chan-Hui P. Y., Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 2010 326 285 289
90. Stamatatos L., Morris L., Burton D. R., Mascola J. R., Neutralizing antibodies generated during natural HIV-1 infection: good news for an HIV-1 vaccine? Nature Medicine 2009 15 866 870 2-s2.0-66449106428 10.1038/nm.1949
91. Trkola A., Pomales A. B., Yuan H., Korber B., Maddon P. J., Allaway G. P., Katinger H., Barbas C. F., Burton D. R., Ho D. D., Moore J. P., Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-IgG. Journal of Virology 1995 69 11 6609 6617 2-s2.0-0028865465
92. Burton D. R., Pyati J., Koduri R., Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. Science 1994 266 1024 1027
93. Kwong P. D., Wilson I. A., HIV-1 and influenza antibodies: seeing antigens in new ways. Nature Immunology 2009 10 6 573 578 2-s2.0-65749107719 10.1038/ni.1746
94. Simek M. D., Rida W., Priddy F. H., Pung P., Carrow E., Laufer D. S., Lehrman J. K., Boaz M., Tarragona-Fiol T., Miiro G., Birungi J., Pozniak A., McPhee D. A., Manigart O., Karita E., Inwoley A., Jaoko W., DeHovitz J., Bekker L. G., Pitisuttithum P., Paris R., Walker L. M., Poignard P., Wrin T., Fast P. E., Burton D. R., Koff W. C., Human immunodeficiency virus type 1 elite neutralizers: individuals with broad and potent neutralizing activity identified by using a high-throughput neutralization assay together with an analytical selection algorithm. Journal of Virology 2009 83 14 7337 7348 2-s2.0-67650453747 10.1128/JVI.00110-09
95. Mascola J. R., Lewis M. G., Stiegler G., Protection of macaques against pathogenic simian/humanimmunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies. Journal of Virology 1999 73 4009 4018
96. Whaley K. J., Zeitlin L., Antibodies as mucosal protectants. Annales de l'Institut Pasteur/Actualites 2001 7 83 100 2-s2.0-0034741950
97. Klein F., Halper-Stromberg A., Horwitz J. A., HIV therapy by a combination of broadly neutralizing antibodies in humanized mice. Nature 2012 492 7427 118 122
98. Doria-Rose N. A., Louder M. K., Yang Z., HIV-1 neutralization coverage is improved by combining monoclonal antibodies that target independent epitopes. Journal of Virology 2012 86 6 3393 3397
99. Mancini N., Solforosi L., Clementi N., De Marco D., Clementi M., Burioni R., A potential role for monoclonal antibodies in prophylactic and therapeutic treatment of influenza. Antiviral Research 2011 92 15 26
100. Hinton P. R., Xiong J. M., Johlfs M. G., Tang M. T., Keller S., Tsurushita N., An engineered human IgG1 antibody with longer serum half-life. Journal of Immunology 2006 176 1 346 356 2-s2.0-29644434678
101. Poignard P., Sabbe R., Picchio G. R., Wang M., Gulizia R. J., Katinger H., Parren P. W. H. I., Mosier D. E., Burton D. R., Neutralizing antibodies have limited effects on the control of established HIV-1 infection in vivo. Immunity 1999 10 4 431 438 2-s2.0-0033119374 10.1016/S1074-7613(00)80043-6
102. Mehandru S., Vcelar B., Wrin T., Stiegler G., Joos B., Mohri H., Boden D., Galovich J., Tenner-Racz K., Racz P., Carrington M., Petropoulos C., Katinger H., Markowitz M., Adjunctive passive immunotherapy in human immunodeficiency virus type 1-infected individuals treated with antiviral therapy during acute and early infection. Journal of Virology 2007 81 20 11016 11031 2-s2.0-35148864699 10.1128/JVI.01340-07
103. Trkola A., Kuster H., Rusert P., Joos B., Fischer M., Leemann C., Manrique A., Huber M., Rehr M., Oxenius A., Weber R., Stiegler G., Vcelar B., Katinger H., Aceto L., Günthard H. F., Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies. Nature Medicine 2005 11 6 615 622 2-s2.0-20944446452 10.1038/nm1244
104. Nimmerjahn F., Ravetch J. V., Antibody-mediated modulation of immune responses. Immunological Reviews 2010 236 265 275
105. Ng C. T., Jaworski J. P., Jayaraman P., Sutton W. F., Delio P., Kuller L., Anderson D., Landucci G., Richardson B. A., Burton D. R., Forthal D. N., Haigwood N. L., Passive neutralizing antibody controls SHIV viremia and enhances B cell responses in infant macaques. Nature Medicine 2010 16 10 1117 1119 2-s2.0-77957820631 10.1038/nm.2233
106. Veselinovic M., Neff C. P., Mulder L. R., Akkina R., Topical gel formulation of broadly neutralizing anti-HIV-1 monoclonal antibody VRC01 confers protection against HIV-1 vaginal challenge in a humanized mouse model. Virology 2012 432 2 505 510
107. Morris G., Chindove S., Woodhall S., A prospective randomized double blind placebo-controlled phase 1 pharmacokinetic and safety study of a vaginal microbicide gel containing three potent broadly neutralizing monoclonal antibodies (2F5, 2G12, 4E10) (MabGel). Microbicides 2010 Abstract LB1
108. Anderson D. J., Politch J. A., Nadolski A. M., Blaskewicz C. D., Pudney J., Mayer K. H., Targeting trojan horse leukocytes for hiv prevention. AIDS 2010 24 2 163 187 2-s2.0-74249104684 10.1097/QAD.0b013e32833424c8
109. Abela I. A., Berlinger L., Schanz M., Reynell L., Günthard H. F., Rusert P., Trkola A., Cell-cell transmission enables HIV-1 to evade inhibition by potent CD4bs directed antibodies. PLOS Pathogens 2012 8 4 e1002634
110. Sagar M., Akiyama H., Etemad B., Ramirez N., Freitas I., Gummuluru S., Transmembrane domain membrane proximal external region but not surface unit-directed broadly neutralizing HIV-1 antibodies can restrict dendritic cell-mediated HIV-1 trans-infection. Journal of Infectious Diseases 2012 205 8 1248 1257
111. Moody M. A., Liao H. X., Alam S. M., Scearce R. M., Plonk M. K., Kozink D. M., Drinker M. S., Zhang R., Xia S. M., Sutherland L. L., Tomaras G. D., Giles I. P., Kappes J. C., Ochsenbauer-Jambor C., Edmonds T. G., Soares M., Barbero G., Forthal D. N., Landucci G., Chang C., King S. W., Kavlie A., Denny T. N., Hwang K. K., Chen P. P., Thorpe P. E., Montefiori D. C., Haynes B. F., Anti-phospholipid human monoclonal antibodies inhibit CCR5-tropic HIV-1 and induce β -chemokines. Journal of Experimental Medicine 2010 207 4 763 776 2-s2.0-77951080820 10.1084/jem.20091281
112. Frandsen T. P., Næsted H., Rasmussen S. K., Hauptig P., Wiberg F. C., Rasmussen L. K., Jensen A. M. V., Persson P., Wikén M., Engström A., Jiang Y., Thorpe S. J., Förberg C., Tolstrup A. B., Consistent manufacturing and quality control of a highly complex recombinant polyclonal antibody product for human therapeutic use. Biotechnology and Bioengineering 2011 108 9 2171 2181 2-s2.0-79960471593 10.1002/bit.23166
113. Nayak S., McKenzie R., Fuchs E., Jurao R., Goodwin J., Zimmerman E., An A., Hendrix C., Liu Q., Ma J., Ahene A., Espinosa Y., Griffiss J., Zenilman J., Safety and pharmacokinetics of a novel co-mixture of three monoclonal antibodies against botulism in healthy subjects. Proceedings of the ASM Biodefense Meeting 2013 Washington, DC, USA
114. Stasi R., Rozrolimupab, symphobodies against rhesus D, for the potential prevention of hemolytic disease of the newborn and the treatment of idiopathic thrombocytopenic purpura. Current Opinion in Molecular Therapeutics 2010 12 6 734 740 2-s2.0-79952924019
115. Bakker A. B. H., Python C., Kissling C. J., Pandya P., Marissen W. E., Brink M. F., Lagerwerf F., Worst S., van Corven E., Kostense S., Hartmann K., Weverling G. J., Uytdehaag F., Herzog C., Briggs D. J., Rupprecht C. E., Grimaldi R., Goudsmit J., First administration to humans of a monoclonal antibody cocktail against rabies virus: safety, tolerability, and neutralizing activity. Vaccine 2008 26 47 5922 5927 2-s2.0-55049129776 10.1016/j.vaccine. 2008.08.050
116. Bregenholt S., Haurum J., Pathogen-specific recombinant human polyclonal antibodies: biodefence applications. Expert Opinion on Biological Therapy 2004 4 3 387 396 2-s2.0-1542572660 10.1517/14712598.4.3.387
117. Bregenholt S., Jensen A., Lantto J., Hyldig S., Haurum J. S., Recombinant human polyclonal antibodies: a new class of therapeutic antibodies against viral infections. Current Pharmaceutical Design 2006 12 16 2007 2015 2-s2.0-33744777491 10.2174/138161206777442173
118. Meijer P. J., Andersen P. S., Haahr Hansen M., Steinaa L., Jensen A., Lantto J., Oleksiewicz M. B., Tengbjerg K., Poulsen T. R., Coljee V. W., Bregenholt S., Haurum J. S., Nielsen L. S., Isolation of human antibody repertoires with preservation of the natural heavy and light chain pairing. Journal of Molecular Biology 2006 358 3 764 772 2-s2.0-33646024606 10.1016/j.jmb.2006.02.040
119. Nielsen L. S., Baer A., Mü ller C., Gregersen K., Mønster N. T., Rasmussen S. K., Weilguny D., Tolstrup A. B., Single-batch production of recombinant human polyclonal antibodies. Molecular Biotechnology 2010 45 3 257 266 2-s2.0-77954959328 10.1007/s12033-010-9270-9
120. Tolstrup A. B., Frandsen T. P., Bregenholt S., Development of recombinant human polyclonal antibodies for the treatment of complex human diseases. Expert Opinion on Biological Therapy 2006 6 9 905 912 2-s2.0-33749044654 10.1517/14712598.6.9.905
121. Wiberg F. C., Rasmussen S. K., Frandsen T. P., Rasmussen L. K., Tengbjerg K., Coljee V. W., Sharon J., Yang C. Y., Bregenholt S., Nielsen L. S., Haurum J. S., Tolstrup A. B., Production of target-specific recombinant human polyclonal antibodies in mammalian cells. Biotechnology and Bioengineering 2006 94 2 396 405 2-s2.0-33744498904 10.1002/bit.20865
122. Farid S. S., Process economics of industrial monoclonal antibody manufacture. Journal of Chromatography B 2007 848 1 8 18 2-s2.0-33847613926 10.1016/j.jchromb.2006.07.037
123. Gao J., Cha S., Jonsson R., Opalko J., Peck A. B., Detection of anti-type 3 muscarinic acetylcholine receptor autoantibodies in the sera of Sjögren's syndrome patients by use of a transfected cell line assay. Arthritis and Rheumatism 2004 50 8 2615 2621 2-s2.0-4043140159 10.1002/art.20371
124. Hiatt A., Pauly M., Monoclonal antibodies from plants: a new speed record. Proceedings of the National Academy of Sciences of the United States of America 2006 103 40 14645 14646 2-s2.0-33749530398 10.1073/pnas.0607089103
125. Giritch A., Marillonnet S., Engler C., Van Eldik G., Botterman J., Klimyuk V., Gleba Y., Rapid high-yield expression of full-size IgG antibodies in plants coinfected with noncompeting viral vectros. Proceedings of the National Academy of Sciences of the United States of America 2006 103 40 14701 14706 2-s2.0-33749536223 10.1073/pnas.0606631103
126. Pogue G. P., Vojdani F., Palmer K. E., Production of pharmaceutical-grade recombinant aprotinin and a monoclonal antibody product using plant-based transient expression systems. Plant Biotechnology Journal 2010 8 5 638 654
127. Bosch D., Castilho A., Loos A., Schots A., Steinkellner H., N-Glycosylation of plant-produced recombinant proteins. Current Pharmaceutical Design 2013
128. Forthal D. N., Gach J. S., Landucci G., Jez J., Strasser R., Kunert R., Steinkellner H., Fc-glycosylation influences Fc γ receptor binding and cell-mediated anti-HIV activity of monoclonal antibody 2G12. Journal of Immunology 2010 185 11 6876 6882
129. Arnold J. N., Wormald M. R., Sim R. B., Rudd P. M., Dwek R. A., The impact of glycosylation on the biological function and structure of human immunoglobulins. Annual Review of Immunology 2007 25 21 50 2-s2.0-34247122497 10.1146/annurev.immunol.25.022106.141702
130. Zeitlin L., Bohorov O., Bohorova N., Prophylactic and therapeutic testing of Nicotiana-derived RSV-neutralizing human monoclonal antibodies in the cotton rat model. Monoclonal Antibodies 2013 5 2
131. Georgiev I. S., Doria-Rose N. A., Zhou T., Delineating antibody recognition in polyclonal sera from patterns of HIV-1 isolate neutralization. Science 2013 340 6133 751 756
132. Zhang G., Lu H., Lu Y., Jiang S., Chen Y. H., Neutralization of HIV-1 primary isolate by ELDKWA-specific murine monoclonal antibodies. Immunobiology 2005 210 9 639 645 2-s2.0-27744441119 10.1016/j.imbio.2005.05.025
133. Muster T., Guinea R., Trkola A., Purtscher M., Klima A., Steindl F., Palese P., Katinger H., Cross-neutralizing activity against divergent human immunodeficiency virus type 1 isolates induced by the gp41 sequence ELDKWAS. Journal of Virology 1994 68 6 4031 4034 2-s2.0-0028235930
134. Walker L. M., Huber M., Doores K. J., Broad neutralization coverage of HIV by multiple highly potent antibodies. Nature 2011 477 7365 466 470
135. Huang J., Ofek G., Laub L., Broad and potent neutralization of HIV-1 by a gp41-specific human antibody. Nature 2012 491 7424 406 412
136. Braibant M., Gong E. Y., Plantier J. C., Moreau T., Alessandri E., Simon F., Barin F., Cross-group neutralization of HIV-1 and evidence for conservation of the PG9/PG16 epitopes within divergent groups. AIDS 2013
137. Bonsignori M., Hwang K. K., Chen X., Analysis of a clonal lineage of HIV-1 envelope V2/V3 conformational epitope-specific broadly neutralizing antibodies and their inferred unmutated common ancestors. Journal of Virology 2011 19 9998 10009
138. Corti D., Langedijk J. P. M., Hinz A., Seaman M. S., Vanzetta F., Fernandez-Rodriguez B. M., Silacci C., Pinna D., Jarrossay D., Balla-Jhagjhoorsingh S., Willems B., Zekveld M. J., Dreja H., O'Sullivan E., Pade C., Orkin C., Jeffs S. A., Montefiori D. C., Davis D., Weissenhorn W., McKnight Á.., Heeney J. L., Sallusto F., Sattentau Q. J., Weiss R. A., Lanzavecchia A., Analysis of memory B cell responses and isolation of novel monoclonal antibodies with neutralizing breadth from HIV-1-infected individuals. PLoS ONE 2010 5 1 2-s2.0-77649318846 10.1371/journal.pone.0008805 e8805
139. Wu X., Yang Z. Y., Li Y., Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science 2010 329 856 861
140. Scheid J. F., Mouquet M., Ueberheide B., Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding. Science 2011 333 6049 1633 1637
141. Diskin R., Scheid J. F., Marcovecchio P. M., Increasing the potency and breadth of an HIV antibody by using structure-based rational design. Science 2011 334 6060 1289 1293